Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-68179280
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JNJ-68179280 is an orally administered small molecule drug developed by Janssen Research & Development for the treatment of inflammatory bowel diseases. It is classified as an anti-inflammatory agent, but its precise mechanism of action has not been defined in public sources. The drug is a new molecular entity and has undergone phase 1 clinical trials to assess its safety and tolerability in healthy volunteers[1][2][4].
Beyond the preview
Go deeper on JNJ-68179280.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-68179280.